ANIK Q3 2019 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$208M

Q3 2019 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$30M+10.9% YoY

Gross Profit

$24M80.0% margin

Operating Income

$12M40.6% margin

Net Income

$9M31.0% margin

EPS (Diluted)

$0.64

QoQ Revenue Growth

-2.4%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$10M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$320M

Total Liabilities

$38M

Stockholders' Equity

$282M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$27M	+10.9%
Gross Profit	$24M	$19M	+28.3%
Operating Income	$12M	$9M	+40.5%
Net Income	$9M	$8M	+21.1%

Revenue Segments

Product

$30M50%

Orthobiologics

$27M45%

Manufactured Product, Other

$2M3%

Surgical

$578,0001%

Dermal

$417,0001%

Geographic Segments

UNITED STATES

$24M86%

Europe

$4M14%